CSIMarket
 


Mateon Therapeutics Inc  (OXGN)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

OXGN's Capital Expenditures Growth by Quarter and Year

Mateon Therapeutics Inc's Capital Expenditures results by quarter and year




OXGN Capital Expenditures (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June 0.00 - - -
I Quarter March - - - -
FY   - - - -



OXGN Capital Expenditures second quarter 2020 Y/Y Growth Comment
Mateon Therapeutics Inc in the second quarter recorded Capital Expenditures of $ 0.00 millions.

According to the results reported in the second quarter, Mateon Therapeutics Inc achieved the best Capital Expenditures growth in Biotechnology & Drugs industry. While Mateon Therapeutics Inc' s Capital Expenditures no change of % ranks overall at the positon no. in the second quarter.




OXGN Capital Expenditures ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Mateon Therapeutics Inc's second quarter 2020 Capital Expenditures $ 0.00 millions OXGN's Income Statement
Mateon Therapeutics Inc's second quarter 2019 Capital Expenditures $ 0.00 millions Quarterly OXGN's Income Statement
New: More OXGN's historic Capital Expenditures Growth >>


OXGN Capital Expenditures (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Capital Expenditures second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Capital Expenditures Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Capital Expenditures second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Capital Expenditures Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Capital Expenditures by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Mateon Therapeutics Inc's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


OXGN's II. Quarter Q/Q Capital Expenditures Comment


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


OXGN's II. Quarter Q/Q Capital Expenditures Comment


Mateon Therapeutics Inc's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
12 Months Ending
(Dec 31 2019)
12 Months Ending
(Sep 30 2019)
12 Months Ending
(Jun 30 2019)
Cumulative Capital Expenditures 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Capital Expenditures Growth (TTM) - - - - -
Year on Year Capital Expenditures Growth Overall Ranking # # # # #
Seqeuential Capital Expenditures Change (TTM) - - - - -
Seq. Capital Expenditures Growth (TTM) Overall Ranking # # # # #




Cumulative Capital Expenditures growth Comment
In the Jun 30 2020 period, Mateon Therapeutics Inc's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

Mateon Therapeutics Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Capital Expenditures growth Comment
In the Jun 30 2020 period, Mateon Therapeutics Inc's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

Mateon Therapeutics Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Capital Expenditures Growth
Biotechnology & Drugs Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
OXGN's Capital Expenditures Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for OXGN's Competitors
Capital Expenditures Growth for Mateon Therapeutics Inc's Suppliers
Capital Expenditures Growth for OXGN's Customers

You may also want to know
OXGN's Annual Growth Rates OXGN's Profitability Ratios OXGN's Asset Turnover Ratio OXGN's Dividend Growth
OXGN's Roe OXGN's Valuation Ratios OXGN's Financial Strength Ratios OXGN's Dividend Payout Ratio
OXGN's Roa OXGN's Inventory Turnover Ratio OXGN's Growth Rates OXGN's Dividend Comparisons



Companies with similar Capital Expenditures no change for the quarter ending Jun 30 2020 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Jun 30 2020
Phibro Animal Health Corp -0.41 %$ -0.405 millions
Veracyte Inc -1.52 %$ -1.517 millions
Akcea Therapeutics Inc -2.51 %$ -2.514 millions
Encompass Health Corporation -2.89 %$ -2.886 millions
Quest Diagnostics Inc -3.53 %$ -3.529 millions
Tcr2 therapeutics Inc -3.72 %$ -3.718 millions
Momenta Pharmaceuticals inc -4.67 %$ -4.674 millions
Moleculin Biotech Inc -5.26 %$ -5.263 millions
Biolife Solutions Inc -5.41 %$ -5.405 millions
Biotelemetry Inc -5.87 %$ -5.875 millions
Optinose Inc -6.27 %$ -6.275 millions
Baxter International Inc -6.49 %$ -6.494 millions
Haemonetics Corp -6.70 %$ -6.704 millions
Lannett Co Inc -8.25 %$ -8.247 millions
Healthcare Services Group Inc -9.74 %$ -9.741 millions
Mednax Inc -9.81 %$ -9.813 millions
X4 Pharmaceuticals Inc -10.00 %$ -10.000 millions
United Therapeutics Corporation -10.34 %$ -10.345 millions
Agenus Inc -11.34 %$ -11.340 millions
Integrated Biopharma Inc -12.50 %$ -12.500 millions
Zoetis Inc -12.62 %$ -12.621 millions
Resmed Inc -12.74 %$ -12.735 millions
Biomarin Pharmaceutical Inc -12.80 %$ -12.802 millions
Nabriva Therapeutics Plc -13.33 %$ -13.333 millions
Vaso Corp -13.82 %$ -13.816 millions
Voyager Therapeutics Inc -13.91 %$ -13.907 millions
Chemed Corporation -14.48 %$ -14.482 millions
Merck and Co Inc -14.58 %$ -14.578 millions
Becton Dickinson And Company -14.77 %$ -14.768 millions
Repligen Corp -15.49 %$ -15.488 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

PEYE's Profile

Stock Price

PEYE's Financials

Business Description

Fundamentals

Charts & Quotes

PEYE's News

Suppliers

PEYE's Competitors

Customers & Markets

Economic Indicators

PEYE's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2020 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071